TQB6411 / Sino Biopharm - LARVOL DELTA

Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer (clinicaltrials.gov) - P1/2 | N=105 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Esophageal Cancer • Oncology

Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer (clinicaltrials.gov) - P1/2 | N=105 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1/2 trial • Esophageal Cancer • Oncology

A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection (clinicaltrials.gov) - P1/2 | N=465 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1/2 trial • Lung Cancer • Oncology • Solid Tumor

TQB6411-I-01: A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=216 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

COMPLETION OF FIRST SUBJECT DOSING OF CLASS 1 INNOVATIVE DRUG TQB6411 (EGFR/c-MET BISPECIFIC ADC) (HKEXnews) - "The board of directors (the 'Board') of Sino Biopharmaceutical Limited (the 'Company', together with its subsidiaries, the 'Group') announces that the Group’s self-developed Class 1 innovative drug, TQB6411 for injection (EGFR/c-Met bispecific ADC), has recently completed the first subject enrollment and successful dosing in a Phase I clinical study in the PRC. TQB6411 was approved by the National Medical Products Administration (NMPA) of the PRC on 13 June to commence clinical trials, intended for the treatment of advanced malignant tumors."

Trial status • Solid Tumor

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=216 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

New P1 trial • Solid Tumor

China's first innovative Class 1 EGFR/c-Met dual-antibody ADC approved for clinical trials [Google translation] (Sino Biopharm Press Release) - "Recently, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration showed that the first-class innovative drug TQB6411 injection independently developed by Sino Biopharmaceutical...subsidiary Chia Tai Tianqing was approved for clinical use for the first time and is intended to be used to treat advanced malignant tumors. TQB6411 is an antibody-drug conjugate (ADC) targeting EGFR/c-Met, and preclinical studies have confirmed that it has good anti-tumor potential."

New trial • Oncology

APPLICATION FOR CLINICAL TRIAL OF “TQB6411 (EGFR/C-MET BISPECIFIC ADC)” ACCEPTED BY CDE (HKEXnews) - "The board of directors (the 'Board') of Sino Biopharmaceutical Limited (the 'Company', togetherwith its subsidiaries, the 'Group') announces that the application for clinical trial of the Group’s selfdeveloped 'TQB6411 (EGFR/c-Met bispecific ADC)' has been submitted to and accepted by the Centerfor Drug Evaluation (CDE) of the National Medical Products Administration of China....TQB6411 is an antibody-drug conjugate (ADC) targeting EGFR and c-Met."

New trial • Oncology